Charles River Laboratories has closed its bid for two CROs formerly owned by drug developer Galapagos, trading $179 million up front and up to $7 million down the line for Argenta and BioFocus.
Ireland's Mallinckrodt has been on a major growth spurt since its spinoff last spring from medical device maker Covidien--and it made another big move Monday in its bid to become a major specialty pharma company.
Sun Pharmaceutical has been shopping for deals that would give it more exposure to the U.S. market, and now it has pulled off a stunner. The Indian drugmaker will pay $3.2 million to buy competitor Ranbaxy Laboratories, a company with serious issues but one with big potential in the world's largest market.
AMRI has wrapped up its $41 million effort to acquire contract manufacturer Cedarburg Pharmaceuticals, and the company says it's in line for an immediate windfall.
Just four months after closing its $1.75 billion acquisition of Agila Specialities, generic drug maker Mylan is eyeing another takeover candidate--Sweden's Meda AB. Pennsylvania-based Mylan is talking with advisers about a takeover bid that could be made at a "significant premium" to Meda's $4.5 billion market value, according to sources quoted by the Financial Times.
The dealmakers at Celgene like to get really, really close to their biotech partners. And nothing demonstrates the sincerity of their interest in new technologies better than the acquisition of a nice big chunk of equity.
Cardinal Health is snatching up California devicemaker AccessClosure for $320 million in cash, a deal that will give the Ohio healthcare services giant a line of cutting-edge vascular closure surgical devices.
Straumann, the Swiss dental implant giant, is sinking $30 million into a low-priced competitor in South Korea with an option to buy a majority stake down the line.
GE Healthcare is looking to cash in on the march toward hospital efficiency. It announced the acquisition of operating room management and analytics solutions provider CHCA Computer Systems today for an undisclosed amount. The deal is expected to close in the second quarter of 2014.
Baxter is buying out collaborator Chatham Therapeutics for $70 million, planning to absorb the gene therapy specialist into its growing hemophilia R&D operation as it prepares to separate its drug and device businesses next year.